PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		11) International Publication Number: WO 99/29331
A61K 35/78, 31/35	A1	43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/EP (22) International Filing Date: 30 November 1998 ((30) Priority Data: Mi97A002690 4 December 1997 (04.12.97) (71) Applicant (for all designated States except US): S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano ((72) Inventors; and (75) Inventors/Applicants (for US only): MORAZZON [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT) BARDELLI, Ezio [IT/IT]; Via Val di Sole, 22, Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja Rossini, 8, I-20122 Milano (IT).	30.11.9 INDEN (IT). NI, Pac). BOI , I–201	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of
AGENTS (57) Abstract		EXTRACTS OF VITIS VINIFERA AS ANTI-ATHEROSCLEROTIC seful for the prevention and the treatment of atherosclerotic pathological

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
ВG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway .	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
Cυ	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THE USE OF PHOSPHOLIPID COMPLEXES OF EXTRACTS OF VITIS VINIFERA AS ANTI-ATHEROSCLEROTIC AGENTS

The present invention relates to the use of phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from *Vitis vinifera* for the preparation of medicaments for the treatment and the prophylaxis of atherosclerosis, and of miocardiac and cerebral infarctions.

The extracts of *Vitis vinifera* are already known and used in the therapy of cardiovascular disorders connected with venous insufficiency, in the treatment of impaired conditions of capillary permeability and resistance and in cicatrization. These extracts, which can be obtained from the seeds of the plant as described in GB-A-1,541,469 or in FR-A-2,092,743, are a mixture of polyphenols such as epicatechin and its polymerization products, in part esterified at the C-3 hydroxyl of the monomer with gallic acid. The phospholipid complexes of the extracts of *Vitis vinifera* are described in US-4,963,527 and are at present commercially available under the trade mark Leucoselect.

10

15

20

It has now surprisingly been found that the complexes prepared according to US-4,963,527 exert, when administered systemically, preferably by the oral route, a marked anti-atherosclerotic activity both in animals and in humans.

25 More specifically, it has been found that the phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from Vitis vinifera, prevent or reduce the formation of athero-

.

sclerotic plagues in a dose-depending relationship.

5

10

15

20

25

30

Such an activity was evidenced in rabbits fed with hypercholesterolemic diet, so as to induce atherosclerotic lesions similar to the human ones at the vascular level, particularly at the aortic arch, ventral aorta, carotids and cerebral vessels. In said model, the above mentioned phospholipid complexes change the macro and microscopical vascular condition reducing, compared with untreated animals, both the number of atheromatous plaques and their severity, with a surprising vasculartissular benefit. In another atherosclerosis model, with the purpose of cerebral protection, wherein the vasal lumen of rabbit internal carotid had been surgically reduced, while administering a hypercholesterolemic diet fats, a decrease in saturated obstruction, a reduction of vessel walls thickness and an increased survival of the animals were evidenced. Furthermore, in atherosclerotic patients, a reduction in carotid obstruction due to atheromatous plaques and an flow, evaluated by Doppler improved carotid ultrasonography, were observed.

The phospholipid complexes of the proanthocyanidins extracted from *Vitis vinifera* can be used in suitable oral formulations, such as tablets, soft— or hard-gelatin capsules, at dosages ranging from 50 to 500 mg two-three times a day, depending on the severity of the disease to treat. The preparation of the pharmaceutical formulations can be carried out according to conventional techniques and excipients.

The following examples illustrate the invention in greater detail.

3 Example 1

3 groups of 8 New Zealand rabbits each, were treated as follows:

Group 1): Control, normal diet

5 Group 2): Hypercholesterolemic diet (0.2% cholesterol)

Group 3): Hypercholesterolemic diet + phospholipid complex of extracts of Vitis vinifera (0.2% cholesterol + 2% Leucoselect(R)).

After 8 weeks, during which cholesterol, LDL/VLDL, HDL and triglycerids levels were measured, the animals were killed.

The number, the size and the distribution of the atherosclerotic lesions on thoracic and abdominal aorta were evaluated.

Aorta strips were fixed and stained with Sudan IV to visualize the lesions and to evaluate the vasal cholesterol and the content in oxidized cholesterol by gaschromatography.

The results reported in the following table prove that the treatment with phospholipid complexes of extracts of *Vitis vinifera* decreases in a statistically significant way the atherosclerotic lesions induced by hypercholesterolemic diet.

Table

25	Treatment	area percent of the lesion
	Group 1	1%
	Group 2	27%
•	Group 3	5%*

^{*}p<0.01 compared with group 2

20

10

Example 2

	Example 2		
	Capsules containing 500 mg of phospholipi	d complex	of
	extracts of Vitis vinifera		
	Composition:		
5	Complex of extract of Vitis vinifera		
	with soy phosphatidylcholine	200	mg
	Lactose	57	mg
	Modified starch	40	mg
	Magnesium stearate	3,0	mg .
10	Example 3		
	Gastro-resistant tablets		
	Complex of extract of Vitis vinifera		
	with soy phosphatidylcholine		mg
	Microcrystalline cellulose		mg
15	Precipitated silica		mg
	Magnesium stearate	4	mg
	Methacrylic acid anionic		
	polymer and esters thereof		2 mg
	Talc	-	3 mg
20	Magnesium carbonate		3 .mg
	Maize star		5 mg
	Gum arabic	15	9 mg
	Example 4		
	Soft-gelatin capsules		
25	Complex of extract of Vitis vinifera		.
	with soy phosphatidylcholine		6 mg
	Peanut oil		9 mg
	Partially hydrogenated vegetable oils	10	0 mg
	Soy lecithin		5 mg

5

CLAIMS

5

20

- 1. The use of phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from *Vitis vinifera* for the preparation of medicaments for the therapeutical and prophylactic treatment of atherosclerosis and of miocardiac and cerebral infarctions.
- 2. The use as claimed in claim 1, wherein the unitary 10 dosage of the medicament ranges from 50 to 500 mg of active ingredient.
 - 3. The use as claimed in claim 1 or 2, wherein the medicament is administrable orally.
- 4. The use as claimed in claim 3, wherein the medicament is in the form of soft- or hard- gelatin capsules or of tablets.
 - 5. A method for the treatment of atherosclerosis and of miocardiac and cerebral infarctions, which comprises administering a patient with an effective amount of a phospholipid complex of extract of *Vitis vinifera*.

Inters and Application No PCT/EP 98/07662

A. CLASSIF IPC 6	rication of subject matter A61K35/78 A61K31/35			
According to	International Patent Classification (IPC) or to both national classificat	ion and IPC		
B. FIELDS S				
IPC 6	cumentation searched (classification system followed by classification $A61K$			
	ion searched other than minimum documentation to the extent that su			
Electronic da	ata base consulted during the international search (name of data bas	e and, where practical,	search terme used)	
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to	claim No.
х	US 4 963 527 A (BOMBARDELLI EZIO 16 October 1990 cited in the application see column 2, line 38 - line 63	ET AL)	1-5	
X	EP 0 713 706 A (SUNTORY LTD) 29 M see page 3, line 28 - page 4, lin		1	
A	K. TEBIB ET AL.: "ANTIOXYDANT EF DIETARY POLYMERIC GRAPE SEED TANN TISSUES OF RATS FED A HIGH CHOLESTEROL-VITAMIN E -DEFICIENT FOOD CHEMISTRY, vol. 59, no. 1, 1997, pages 135-1 XP002098281	INS IN DIET"	•	
X Furt	ther documents are listed in the continuation of box C.	X Patent family	members are listed in annex.	
"A" docum consis "E" earlier filling "L" docum which citatic "O" docum other	nent which may throw doubts on priority claim(s) or it is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or remains means the priority of the international filling date but than the priority date claimed	or priority date and cited to understand invention. "X" document of particities and invention of carricities and invention of particities and occument of particities and occument is combinents, such combin the art. "&" document member	lished after the international filing date d not in conflict with the application but d the principle or theory underlying the ular relevance; the claimed invention ared novel or cannot be considered to sets when the document is taken alwair relevance; the claimed invention ared to involve an inventive step when the document with one or more other such document of the same patent family	one the
	e actual completion of the international search	Date of mailing of	the international search report .	
	mailing address of the ISA	Authorized officer		•
	European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijawijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Rempp,	G	

Form PCT/ISA/210 (second sheet) (July 1992)

Interr nel Application No PCT/EP 98/07662

lon) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
E. BOMBARDELLI ET AL.: "BIOLOGICAL ACTIVITY OF PROCYANIDINS FROM VITIS VINIFERA L." BIOFACTORS, vol. 6, no. 4, 1997, pages 429-431, XP002098282	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

1

PCT/EP 98/ 07662

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inter	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	Claims Nos.: 5 because they relate to subject matter not required to be searched by this Authority, namely: See FURTHER INFORMATION SHEET PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rema	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

International Application No. PCT/EP 98 \(D)7662
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
Although claim 5 IS directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: 5
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

.

information on patent family members

Interr nal Application No
PCT/EP 98/07662

Patent document cited in search report		Publication date		atent family nember(s)	Publication date
US 4963527	A	16-10-1990	AT	91688 T	15-08-1993
			CA	1337604 A	21-11-1995
			DE	3882383 A	26-08-1993
			DE	3882383 ·T	11-11-1993
			EP	0275224 A	20-07-1988
			ES	2056943 T	16-10-1994
			JP	1013031 A	17-01-1989
			JP	1954097 C	28-07-1995
			JP	6076335 B	28-09-1994
			PT	86509 B	31-12-1991
EP 0713706	Α	29-05-1996	FI	955691 A	29-05-1996
LI 0/13/00	"	23 00 2330	JР	8225453 A	03-09-1996
			NO	954834 A	29-05-1996
			ÜS	5607965 A	04-03-1997

Form PCT/ISA/210 (patent family annex) (July 1992)